



USE OF FIRST-LINE PSYCHOSOCIAL CARE FOR CHILDREN AND ADOLESCENTS ON ANTIPSYCHOTICS (APP)

MEETING THE HEDIS MEASURE

The APP measure assesses the percentage of children and adolescents newly started on antipsychotic medications without a clinical indication who had documentation of psychosocial care as first-line treatment.

Two age groups are reported for this measure:

- Ages 1-11
- Ages 12-17

WHY IS THE APP MEASURE IMPORTANT?

Although antipsychotic medications may serve as effective treatment for a narrowly defined set of psychiatric disorders in children and adolescents, they are often prescribed for nonpsychotic conditions for which psychosocial interventions are considered first-line treatment. Safer, first-line psychosocial interventions may be underutilized, and children and adolescents may unnecessarily incur the risks associated with antipsychotic medications.

Psychosocial care, which includes behavioral interventions, psychological therapies, and skills training, among others, is the recommended first-line treatment option for children and adolescents diagnosed with nonpsychotic conditions such as attention-deficit disorder and disruptive behaviors.

WHAT CAN BE DONE TO HELP MEET THE MEASURE?

When prescribed, antipsychotic medications should be part of a comprehensive, multi-modal plan for coordinated treatment that includes psychosocial care.

Periodically review the ongoing need for continued therapy with antipsychotic medications.

Assess the need for Case Management and refer if necessary.

Ensure progress notes are complete and accurate.

Before prescribing an antipsychotic medication, assess the member's treatment and medication history.

Before prescribing an antipsychotic medication for a diagnosis for which it is not indicated, utilize psychosocial care as first-line treatment.

If psychosocial care cannot be utilized as first-line treatment before prescribing an antipsychotic medication for a diagnosis for which it is not indicated, start psychosocial care within 30 days.

Involve the member's parent/guardian/family/support system and/or significant other regarding medications and psychosocial care.

Assist member with coordination of psychosocial care with appropriate referrals and scheduling.

Talk frankly about the importance of psychosocial care to help the member engage in treatment.

Ensure the member has an appointment scheduled within 30 days of prescribing an antipsychotic medication

Schedule psychosocial care within 20 days of prescribing an antipsychotic medication. If the appointment is missed, this will allow flexibility in rescheduling within 30 days.

Before scheduling an appointment, verify with the member that it is a good fit considering things like transportation, location, and time of the appointment. Identify and address any barriers to member keeping appointment.

Provide reminder calls to confirm appointment.

Reach out proactively within 24 hours if the member does not keep scheduled appointment to schedule another.

Provide timely submission of claims.

Providers maintain appointment availability for members prescribed an antipsychotic medication.

If antipsychotics are prescribed with psychosocial care, educate the member and the parents/guardians/family/support system and/or significant other about possible side effects of medications

and what to do if side effects appear. Reinforce the treatment plan and evaluate the medication regimen considering presence/absence of side effects, potential costs, clear written instructions for medication schedule, etc.

Encourage communication between the behavioral health specialist and PCP (Primary Care Provider). Ensure that the member has a PCP and that care transition plans with the PCP are shared

REQUIREMENTS

No special requirements

SERVICE DATE RANGE

January 1 through December 1 of the measurement year.

REQUIRED EXCLUSIONS

Exclude members who meet any of the following criteria:

- Members for whom first-line antipsychotic medications may be clinically appropriate: members with a diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, other psychotic disorder, autism or other developmental disorder (Schizophrenia Value Set; Bipolar Disorder Value Set; Other Psychotic and Developmental Disorders Value Set) on at least two different dates of service during the measurement year. Do not include laboratory claims (claims with POS code 81).
- Members in hospice or using hospice services during the measurement year
- Members who have died during the measurement year

 Antipsychotic Medications				
Medications	Other Prescription Names			
Miscellaneous Antipsychotic Agents				
Aripiprazole	Abilify	Abilify Discmelt	Abilify Mycite	
Asenapine-	Saphris	Secuado	Sycrest	
Brexipiprazole	Rexulti			
Cariprazine	Reagila	Vraylar		
Clozapine	Clozari Denzapine	FazaClo	Versacloz	Zaponex
Haloperidol	Haldol	Haloperidol decanoate	Serenace	
Haloperidol decanoate	Haldol	Haloperidol LA	Peridol	
lloperidone	Fanapt	Fanapt Titration Pack		
Loxapine	Adasuve	Loxitane		
Lurasidone	Latuda			
Molindone	Moban	Molindone Hydrochloride Tablets		
Olanzapine	ZyPREXA	ZyPREXA Zydis		
Paliperidone	Invega	Xeplion	Trevicta	
Paliperidone palmitate	Invega Hafyera	Invega Sustenna	Invega Trinza	
Perphenazine	Etrafon/Triavil/Triptafen	Trilafon (single drug)		
Pimozide	Orap			
Quetiapine	Seroquel (immediate-release tablet)	Seroquel XR		
Risperidone	Risperdal	Risperdal Consta	Risperdal M-Tab	
Ziprasidone	Geodon	Zeldox	Zipwell	



Antipsychotic Medications Continued

Phenothiazine Antipsychotics

Chlorpromazine				
Fluphenazine	Modecate Modecate Concentrate	Moditen	Prolixin (D/C'd)	RhoFluphenazine
Fluphenazine decanoate	Permitil	Prolixin		
Perphenazine				
Thioridazine	Mellaril / Melleril			
Trifluoperazine	Eskazine Eskazinyl Jatroneural	Modalina Sizonil Stelazine	Stilizan Terfluzine Trifluoperaz	Triftazin

Thioxanthenes

Thiothixene	Navane			
-------------	--------	--	--	--

Long-acting injections

Aripiprazole				
Aripiprazole lauroxil				
Fluphenazine decanoate				
Haloperidol decanoate				
Olanzapine				
Paliperidone palmitate				
Risperidone				

Antipsychotic Combination Medications

Psychotherapeutic combinations

Fluoxetine-olanzapine				
Perphenazine-amitriptyline				

Canadian Prescription Name

Aripiprazole	APO-ARIPiprazole ARIPiprazole	AURO-ARIPiprazole MINT-ARIPiprazole	Sandoz ARIPiprazole Pms-ARIPiprazole	TEVA-ARIPiprazole
Haloperidol	Alti-Haloperidol Apo-Haloperidol	Novo-Peridol Peridol	Pms-Haloperidol	Ratio-Haloperido
Paliperidone	Mar-Paliperidone	Mylan-Paliperidone		
Risperidone	Act risperidone AG-risperiDONE APO-risperiDONE	DOM-risperiDONE IPG-risperiDONE JAMP-risperiDONE	DOM-risperiDONE IPG-risperiDONE JAMP-risperiDONE	RAN-risperiDONE RisperDAL RIVA-risperiDONE

India Prescription Name

Lurasidone	Alsiva Atlura Emsidon Latuda	Lurace Lurafic Lurakem Luramax (Sun Pharma)	Lurasid Lurastar Lurata Luratrend	Tablura Unison
------------	---------------------------------------	--	--	-------------------

COMMONLY USED CODES*

CPT® / CPT® II Electronic Clinical Data System (ECDS)	
Psychosocial Care	90832, 90833, 90834, 90836, 90837, 90838, 90839, 90840, 90845, 90846, 90847, 90849, 90853, 90875, 90876, 90880 HCPCS: G0176, G0177, G0409, G0410, G0411, H0004, H0035, H0036, H0037, H0038, H0039, H0040, H2000, H2001, H2011, H2012, H2013, H2014, H2017, H2018, H2019, H2020, S0201, S9480, S9484, S9485
Residential Behavioral Health Treatment	HCPCS: H0017, H0018, H0019, T2048
ICD-10 Codes	
Bipolar Disorder	F30.10, F30.11, F30.12, F30.13, F30.2, F30.3, F30.4, F30.8, F30.9, F31.0, F31.10, F31.11, F31.12, F31.13, F31.2, F31.30, F31.31, F31.32, F31.4, F31.5, F31.60, F31.61, F31.62, F31.63, F31.64, F31.70, F31.71, F31.72, F31.73, F31.74, F31.75, F31.76, F31.77, F31.78
Other Psychotic and Developmental Disorders	F22, F23, F24, F28, F29, F32.3, F33.3, F84.0, F84.2, F84.3, F84.5, F84.8, F84.9, F95.0, F95.1, F95.2, F95.8, F95.9
Schizophrenia	F20.0, F20.1, F20.2, F20.3, F20.5, F20.81, F20.89, F20.9, F25.0, F25.1, F25.8, F25.9

*Codes are not all inclusive

**Claims data only, cannot accept data through any other supplemental sources such as data feeds and medical record collection methods.

REFERENCES

Use of first line psychosocial care for children and adolescents on anti-psychotics. NCQA. (2023d, January 23). <https://www.ncqa.org/hedis/measures/use-of-first-line-psychosocial-care-for-children-and-adolescents-on-anti-psychotics/>

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). CPT® is a registered trademark of the American Medical Association. Aetna; Better Health of Ohio; OhioRISE will make the final determination regarding reimbursement upon receipt of a claim. Submitting a claim with a code included in this document is not a guarantee of payment. Payment of covered services is contingent upon coverage within an individual member's benefit plan, your eligibility for payment, any claim processing requirements, and your participation agreement with Aetna; Better Health of Ohio; OhioRISE.